- ￥440 - 1320
- CUSABIO
- 武汉
- CSB-PA308125HA01DEZ
- 2025年07月04日
- ELISA
- Rabbit
- Drimia maritima
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Drimia maritima Ribosome-inactivating protein charybdin protein (1-257AA)
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
-20°C
- 克隆性：
多克隆
- 标记物：
Non-conjugated
- 适应物种：
Drimia maritima
- 保质期：
12个月
- 抗原来源：
Drimia maritima
- 目录编号：
CSB-PA308125HA01DEZ
- 级别：
多克隆抗体
- 库存：
充足
- 供应商：
武汉益普生物科技有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA
- 靶点：
Ribosome-inactivating protein charybdin
- 抗体英文名：
Ribosome-inactivating protein charybdin Antibody
- 规格：
20μg/50μg/100μg
| 规格： | 20μg | 产品价格： | ￥440.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
| 规格： | 100μg | 产品价格： | ￥1320.0 |
| 产品名称 | Ribosome-inactivating protein charybdin Antibody |
| 货号 | CSB-PA308125HA01DEZ |
| 别名 | Ribosome-inactivating protein charybdin antibody; EC 3.2.2.22 antibody; rRNA N-glycosidase antibody |
| 抗体类型 | Polyclonal Antibody |
| 克隆类型 | Polyclonal |
| Uniprot No. | P84786 |
| 基因名 | Ribosome-inactivating protein charybdin |
| 免疫原种属 | Drimia maritima |
| 免疫原 | Recombinant Drimia maritima Ribosome-inactivating protein charybdin protein (1-257AA) |
| 宿主 | Rabbit |
| 反应种属 | Drimia maritima |
| 应用范围 | ELISA |
| 抗体亚型 | IgG |
| 标记方式 | Non-conjugated |
| 产品提供形式 | Liquid |
| 纯化方式 | >95%, Protein G purified |
| 保存缓冲液 | Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 |
| 储存条件 | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Isolation and Purification of Ribosome-Inactivating Proteins
Ribosome-inactivating proteins (RIPs) are cytotoxic N -glycosidases identified in plants, fungi, and bacteria. RIPs inhibit protein synthesis by virtue of their enzymatic activity, selectively cleaving a specific adenine residue from a highly
for the generation of ITs, although several other single-chain ribosome-inactivating proteins (RIPs) or type I RIPs are also available (3 ). Type I RIPs are RNA N -glycosidases displaying potent inhibition of protein synthesis in cell-free assays, but they lack
Ribosome Display and Screening for Protein Therapeutics
in each cycle, enabling selection of antibody variants with improved affinity, specificity, and stability, thus providing a powerful “protein evolution” tool for optimizing antibody therapeutics. Ribosome display selects required molecules by linking individual
技术资料暂无技术资料 索取技术资料
